Clinical trials: Bronchopulmonary Disease
Respiratory Distress Syndrome In Premature Infants, Bronchopulmonary Dysplasia
Seattle-PAP Bubble Nasal CPAP and Work of Breathing
The investigators propose to test the hypothesis that Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) supports respiratory physiology in very low birth weight (VLBW) infants more effectively than standard…
- Conditions
- Respiratory Distress Syndrome In Premature Infants, Bronchopulmonary Dysplasia, Newborn Primary Sleep Apnea
- Trial name
- Seattle-PAP (NCT02210026)
- Testing
- Seattle-PAP
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Seattle Children's Hospital
Infant, Newborn, Infant, Small for Gestational Age
Hydrocortisone for BPD
The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life.
- Conditions
- Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature
- Trial name
- NCT01353313
- Testing
- Hydrocortisone
- Where
- 20 sites in United States
- Volunteers
- 800 people
- Sponsor
- NICHD Neonatal Research Network
Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD)
National Surveillance and Prevention of Neonatal VAP
The goal of this observational study is to improve how hospital-acquired lung infections (called ventilator-associated pneumonia, or VAP) are diagnosed, treated and prevented in very low birth weight (VLBW) infants, babies born…
- Conditions
- Ventilator-Associated Pneumonia (VAP), Neonatal, Bronchopulmonary Dysplasia (BPD), Antibiotic-Resistant Organisms (AROs), Health-Care Associated Infection (HAI)
- Trial name
- NCT07109791
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Alberta
Bronchopulmonary Dysplasia
Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia
OBJECTIVES: I. Estimate the efficacy of cortisol replacement therapy during the first 12 days of life for prevention of bronchopulmonary dysplasia. II.
- Trial name
- NCT00004669
- Testing
- hydrocortisone
- Volunteers
- 40 people
- Sponsor
- National Center for Research Resources (NCRR)